Portal Vein Thrombosis
Portal vein thrombosis (PVT) is the formation of a blood clot in the portal vein, the major vessel that carries blood from the digestive organs and spleen to the liver. PVT can develop suddenly (acute) or evolve slowly over time (chronic). Causes include chronic liver disease and cirrhosis, abdominal infections or inflammation, cancer, blood clotting disorders, and abdominal surgery. Depending on its extent and underlying cause, PVT can cause abdominal pain, gastrointestinal bleeding, ascites, or signs of liver dysfunction. Imaging—particularly Doppler ultrasound, CT, and MR venography—is the central tool for diagnosis.
What is it?
The portal vein is a large vein in the abdomen that carries blood from the digestive organs and spleen to the liver. It is formed by the joining of the superior mesenteric vein (which drains the small intestine, much of the colon, and part of the pancreas) and the splenic vein (which drains the spleen and parts of the stomach and pancreas), and it usually has a tributary from the inferior mesenteric vein. The portal vein carries most of the blood reaching the liver, where the liver processes nutrients, filters toxins, and performs many essential functions. Portal vein thrombosis is the formation of a blood clot in the portal vein or its tributaries, which partially or completely blocks blood flow.
PVT can be classified by timing and extent. Acute PVT develops suddenly, often within days to a few weeks of clot formation, and may be associated with more pronounced symptoms. Chronic PVT evolves over time and is often discovered incidentally; the body may form a network of small collateral veins around the blocked portal vein (a process called cavernous transformation of the portal vein). PVT can be partial or complete and can involve different segments—including the main portal vein, its right or left branches, the superior mesenteric vein, and the splenic vein. Extension into the mesenteric veins is particularly important because it can compromise blood supply to the bowel.
Several factors contribute to PVT and often overlap. Cirrhosis and chronic liver disease are the most common underlying causes in many regions, in part because of slowed blood flow through the liver and other related factors. Cancer—particularly hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer, and other abdominal cancers—can lead to PVT through tumor invasion of the vein or by promoting a clotting tendency. Abdominal infections and inflammatory conditions (such as appendicitis, diverticulitis, pancreatitis, inflammatory bowel disease, and intra-abdominal abscesses) can trigger PVT in nearby tributaries. Surgery in the abdomen—including liver transplantation, splenectomy, bariatric surgery, and bowel surgery—can be associated with PVT. Inherited and acquired clotting disorders (such as factor V Leiden, prothrombin gene mutation, antiphospholipid syndrome, myeloproliferative neoplasms including JAK2-positive disorders, and paroxysmal nocturnal hemoglobinuria) increase risk. Other contributors include certain medications (such as oral contraceptives), pregnancy, and rare conditions affecting blood or vessel walls.
Symptoms depend on the cause, extent, and timing. Acute PVT may produce abdominal pain (sometimes severe), nausea, vomiting, fever, and a general feeling of being unwell. When the clot extends into the mesenteric veins or compromises bowel circulation, symptoms can include severe abdominal pain, bloody stools, and signs of bowel ischemia or sepsis—a surgical emergency. Chronic PVT may cause no symptoms or may present with signs of portal hypertension, such as enlarged spleen, low platelet counts, varices (enlarged veins in the esophagus or stomach that can bleed), ascites (fluid in the abdomen), or upper gastrointestinal bleeding. In cirrhotic patients, PVT may worsen liver function and complicate management or transplant candidacy.
Diagnosis combines clinical assessment, blood tests, and imaging. Doppler ultrasound of the abdomen is often the initial imaging test because it is widely available and can identify a clot in the portal vein and assess flow. CT with intravenous contrast or CT venography provides detailed three-dimensional information and is especially useful for assessing the extent of clot, evaluating the mesenteric veins, looking for underlying causes (such as cancer, infection, or inflammation), and assessing complications such as bowel ischemia. MR venography is an alternative when avoiding radiation or iodinated contrast is preferred. Endoscopic ultrasound may help in selected cases. Blood tests assess liver function, kidney function, infection, and clotting parameters; evaluation for inherited or acquired thrombophilia is often performed, particularly in non-cirrhotic patients.
Important to Know
Management of portal vein thrombosis is highly individualized and depends on whether the condition is acute or chronic, the extent of the clot, the underlying cause, the patient’s bleeding and clotting risk, and overall health. Care is typically coordinated by a multidisciplinary team that may include hepatologists, gastroenterologists, hematologists, interventional radiologists, vascular surgeons, oncologists, infectious disease specialists, and primary care clinicians.
Anticoagulation is a cornerstone of treatment for many patients with PVT, particularly in acute, extensive, or symptomatic cases and in patients without cirrhosis. Anticoagulation aims to prevent further extension of the clot, support natural breakdown of the thrombus, and reduce the risk of complications such as bowel ischemia. Several anticoagulant options exist (including direct oral anticoagulants, low-molecular-weight heparin, and warfarin), with the choice tailored to liver function, kidney function, bleeding risk, and other patient factors. In cirrhotic patients, anticoagulation is increasingly used in selected situations, with careful attention to risks and benefits. In some chronic cases, particularly when cavernous transformation has developed, anticoagulation may be less helpful and management focuses on complications.
Treatment of the underlying cause is essential. This may include treating infection, managing inflammatory disease, treating cancer, addressing inherited or acquired clotting disorders, optimizing care of cirrhosis and portal hypertension, or discontinuing contributing medications.
Catheter-directed therapies—such as transjugular intrahepatic portosystemic shunt (TIPS) and catheter-based thrombolysis or thrombectomy—are used in selected patients, particularly those with significant portal hypertension complications or extensive clot. Surgery is reserved for selected cases, including those requiring management of bowel ischemia, complicated portal hypertension, or other specific scenarios.
Management of complications—including variceal bleeding (often with endoscopic banding, medications such as beta-blockers, and supportive care), ascites, hepatic encephalopathy, and infection—is an important part of long-term care for patients with chronic PVT and portal hypertension. Acute mesenteric ischemia related to extension of PVT into the mesenteric veins is a surgical emergency requiring urgent evaluation and treatment.
Long-term follow-up is important to monitor for clot extension or recurrence, complications of portal hypertension, and effects of treatment. Patients with newly identified clotting disorders may benefit from genetic counseling and screening of family members, depending on the specific diagnosis.
Red flag symptoms include sudden severe abdominal pain, persistent vomiting with severe pain, blood in stool or vomit, jaundice, sudden swelling of the abdomen or legs, signs of shock, high fever with abdominal pain, sudden mental status changes, or sudden severe leg or limb pain with discoloration. These warrant prompt or urgent medical evaluation, as they may indicate complications such as bowel ischemia, variceal bleeding, severe infection, or extension of clot elsewhere.